BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy

Nov 19, 2026

New Preclinical Findings Show TROP2 Levels May Help Predict REQORSA Treatment Response—and That Modifying TROP2 Expression May Increase Cancer Cell Sensitivity to Gene Therapy. Combined With the Roche Diagnostics Collaboration, Expanding TUSC2 Research and Advancing Clinical Programs, Genprex, Inc. (NAS DAQ: GNPX) Is Building Significant Momentum Across Its Innovative Biotechnology Platform.

AUSTIN, Texas - Nov. 19, 2026 - PRLog -- Genprex, Inc. (N A S D A Q: GNPX) $GNPX is bringing another exciting development to its growing gene therapy story with today's November 19 announcement of new preclinical data identifying TROP2 as a potential predictive biomarker for its lead investigational therapy, REQORSA® (quaratusugene ozeplasmid). Presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, the research offers important new insights into how TROP2 expression may influence the response of non-small cell lung cancer (NSCLC) to REQORSA.

What makes today's announcement especially interesting is that researchers are investigating more than simply whether TROP2 can identify patients likely to respond. The new findings also suggest that changing TROP2 expression may influence how cancer cells respond to TUSC2 gene therapy, potentially opening another avenue for improving treatment sensitivity.

For Genprex investors, this represents an important addition to an increasingly sophisticated precision-oncology strategy. The company is working to combine its innovative gene therapy platform with biomarker research that could help researchers better understand treatment response and identify patients who may benefit most.

Today's Big News: TROP2 Research Reveals Another Potential Advantage for REQORSA

The November 19 announcement highlights findings from research titled "TROP2 Predicts Response to TUSC2 Gene Therapy and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment."

Researchers evaluated multiple NSCLC cell lines and patient-derived organoid models to investigate the relationship between TROP2 expression and response to TUSC2 gene delivery.

The findings were particularly noteworthy:
  • Approximately 50% of the 10 NSCLC cell lines evaluated demonstrated primary resistance to TUSC2 gene delivery.
  • Approximately 50% of the 12 patient-derived organoid models also demonstrated primary resistance.
  • Low TROP2 protein expression was consistently associated with primary resistance across multiple preclinical models.
  • Analysis of pretreatment tumor biopsies from patients enrolled in a TUSC2 gene therapy clinical trial provided additional supporting evidence.

Perhaps the most intriguing aspect involved experiments examining whether changing TROP2 expression could influence treatment sensitivity.

Researchers introduced TROP2 into TROP2-low NSCLC cancer cells, including H460 and H1299 models. This significantly increased TUSC2-induced apoptosis, bringing the response to levels similar to cells naturally expressing higher TROP2.

This is an important scientific observation because it suggests TROP2 may have a role beyond simply identifying tumors that respond differently. Modifying its expression could potentially become another research strategy for enhancing REQORSA treatment.

The company believes these findings could help inform future patient-selection strategies and additional research into improving treatment response.

Roche Diagnostics Collaboration: A Powerful Addition to Genprex's Strategy

One of Genprex's most important strategic developments remains its collaboration with Roche Diagnostics, announced August 3.

The collaboration focuses on validating biomarker assays for non-small cell lung cancer, with particular attention to TROP2 and PTEN.

Roche brings extensive diagnostic expertise to the relationship, while Genprex contributes its developing REQORSA gene therapy platform and growing body of clinical and preclinical research.

The objective is to develop a more refined approach to identifying patients who may be more likely to benefit from REQORSA.

Previous clinical research suggested that higher TROP2 expression and lower PTEN expression were associated with longer progression-free survival in certain NSCLC patient groups.

Today's new findings add another important scientific component to this collaboration by providing additional evidence supporting the investigation of TROP2 as a potential predictive biomarker.

Genprex anticipated completing the Roche-related assay validation studies around the end of 2026, with potential incorporation into its NSCLC clinical program following successful validation.

The combination of Roche's diagnostic capabilities and Genprex's gene therapy research could become an important part of the company's precision-medicine strategy.

REQORSA: Advancing an Innovative Approach to Lung Cancer

At the center of Genprex's oncology platform is REQORSA, also known as quaratusugene ozeplasmid.

The investigational therapy is designed to deliver the TUSC2 tumor-suppressor gene into cancer cells using Genprex's proprietary ONCOPREX Delivery System, which utilizes lipid-based nanoparticles.

TUSC2 expression is reduced or absent in more than 80% of NSCLC cases and nearly all small cell lung cancers, making it an important target for investigation.

REQORSA is designed to restore tumor-suppressor activity and influence multiple biological pathways involved in cancer progression, including MAPK and mTOR signaling, cell-cycle regulation and programmed cancer-cell death.

Genprex is advancing two important clinical initiatives:

Acclaim-1: Evaluating REQORSA in combination with AstraZeneca's Tagrisso in patients with advanced NSCLC carrying specific EGFR mutations.

Acclaim-3: Evaluating REQORSA in an extensive-stage small cell lung cancer treatment strategy.

Both programs have received FDA Fast Track designation, while the small cell lung cancer program has also received Orphan Drug Designation.

New TUSC2 Research Expands the Scientific Story

Genprex has also been generating interest through its sponsored research collaboration with Meharry Medical College.

Recent research has examined TUSC2's role in cellular resilience, mitochondrial function and biological processes associated with aging.

On November 5, the company highlighted patient-derived research involving blood samples from 11 lung cancer patients receiving REQORSA. Researchers identified changes in gene-expression patterns associated with mitochondrial adaptation, autophagy, cellular maintenance and protein quality control.

These findings add another dimension to the understanding of TUSC2's biological activity in humans and complement the company's broader scientific investigation.

Diabetes Gene Therapy Adds Another Development Opportunity

Beyond oncology, Genprex is pursuing an additional opportunity through its diabetes gene therapy program.

The approach uses AAV technology to deliver Pdx1 and MafA genes to the pancreas, with the objective of restoring insulin-producing cell function.

Preclinical studies have produced encouraging findings in Type 1 and Type 2 diabetes models, including improvements in glucose control and insulin-related measures.

In August, Genprex announced the selection of a U.S.-based contract development and manufacturing organization to begin manufacturing scale-up for its diabetes gene therapy candidate.

This provides another important development program as the company works toward future clinical research.

The Road Ahead: Important Catalysts for GNPX Investors

Genprex has several important developments to watch as 2026 progresses:
  • Continued investigation of TROP2 as a potential predictive biomarker for REQORSA.
  • Further research into whether TROP2 modulation can enhance treatment sensitivity.
  • Anticipated completion of Roche Diagnostics biomarker assay validation.
  • Continued advancement of the Acclaim-1 and Acclaim-3 clinical programs.
  • Additional TUSC2 research and diabetes gene therapy development.

Genprex Is Building an Intriguing Precision Gene Therapy Platform

Today's November 19 announcement adds another important milestone to Genprex's developing story. The TROP2 findings are particularly interesting because they suggest two potential opportunities: identifying patients more likely to respond to REQORSA and investigating whether changing TROP2 expression could increase treatment sensitivity.

Combined with the Roche Diagnostics collaboration, these findings strengthen the scientific foundation behind Genprex's precision-oncology ambitions.

The company's continued TUSC2 research, advancing lung cancer clinical programs and separate diabetes gene therapy initiative provide multiple areas of development to follow.

For investors watching emerging biotechnology opportunities, Genprex is building an increasingly compelling story around innovative gene therapy, strategic diagnostic collaboration and personalized cancer treatment. With today's new TROP2 findings adding another exciting dimension to REQORSA, GNPX has important scientific milestones ahead as it works to translate its research into meaningful clinical progress.

For more information on $GNPX visit: www.genprex.com and https://compasslivemedia.com/gnpx/

Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: [email protected]
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website

Contact
CorporateAds
***@gmail.com

Photos: (Click photo to enlarge)




Source: CorporateAds

Read Full Story - BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy | More news from this source

Press release distribution by PRLog

More News

Jorrybell Agoto passes away at 31
Nov 19, 2026
Jorrybell Agoto passes away at 31

Jorrybell Agoto, the breakout “Filipiñana” star battled lymphoma and has been in critical care since September.

Victim's lawyers back closed testimony, stronger protection for Duterte ICC trial witnesses
Nov 19, 2026
Victim's lawyers back closed testimony, stronger protection for Duterte ICC trial witnesses

PRAGUE, Czech Republic - Amid the “exceptional circumstances” in former President Rodrigo Duterte"s International Criminal Court (ICC) case, closed sessions and stronger protections for testifying witnesses are necessary, the victims" lawyers tell the Trial Chamber III.

Marcos seeks action on illegal, unregulated fishing at APEC
Nov 19, 2026
Marcos seeks action on illegal, unregulated fishing at APEC

SHENZHEN - President Ferdinand “Bongbong” Marcos Jr. raised the matter of illegal, unreported, and unregulated fishing during the 33rd APEC Economic Leaders' Meeting.

Zaldy Co’s 3 co-accused declared fugitives; Ombudsman calls for action
Nov 19, 2026
Zaldy Co’s 3 co-accused declared fugitives; Ombudsman calls for action

MANILA, Philippines — The Office of the Ombudsman on Thursday expressed hope that the Sandiganbayan Fifth Division’s declaration of former lawmaker Zaldy Co’s three co-accused as fugitives from justice, along with its order to cancel their passports, would prompt concerned government agencies to exhaust all available means to bring them before the courts. In a

Claire Castro downplays playing of 'Anak' for Marcos in China
Nov 19, 2026
Claire Castro downplays playing of 'Anak' for Marcos in China

SHENZHEN, China -- Palace Press Officer Usec. Claire Castro downplayed the playing of the late folk singer-songwriter Freddie Aguilar"s composition “Anak” to welcome President Ferdinand “Bongbong” Marcos Jr. in China for the 33rd APEC Economic Leaders' Meeting.

Group to sue police for protesters’ ‘illegal’ arrest during Asean Summit
Nov 19, 2026
Group to sue police for protesters’ ‘illegal’ arrest during Asean Summit

MANILA, Philippines—The National Union of Peoples’ Lawyers (NUPL) on Thursday said it will file counter charges against police officers who allegedly committed human rights violations. These offenses were reportedly done by the law enforcers when they arrested over 200 individuals during protests held earlier this week during the Asean Summit. In a press briefing, NUPL

Duterte's defense witness admits Cale88 has 'red flags'
Nov 19, 2026
Duterte's defense witness admits Cale88 has 'red flags'

A defense witness in the impeachment trial of Vice President Sara Duterte admitted that there were "red flags" in the operations of Cale88 but said these do not necessarily mean wrongdoing.

Who pays for Rodrigo Duterte's defense? ICC says he does
Nov 19, 2026
Who pays for Rodrigo Duterte's defense? ICC says he does

Former president Rodrigo Duterte bears the legal costs in the crimes against humanity case he faces before the International Criminal Court (ICC), the court has confirmed. In a background document and the updated case page, the ICC Public Affairs Unit explained that in the court"s legal aid system, the former president is “not indigent."

PAWS: NBI finds no animal remains in urns linked to crematorium scam
Nov 19, 2026
PAWS: NBI finds no animal remains in urns linked to crematorium scam

MANILA, Philippines – The National Bureau of Investigation (NBI) found no traces of animal remains in the urns submitted by complainants in the alleged pet crematorium scam, according to Philippine Animal Welfare Society (PAWS) Executive Director Anna Cabrera. “Instead na na nakita ng kanilang forensics lab ay silicone, iron, potassium and aluminum ang contents nung

Cordillera rights group hails acquittal of community doctor, IP advocate
Nov 19, 2026
Cordillera rights group hails acquittal of community doctor, IP advocate

MANILA, Philippines — The Cordillera Human Rights Alliance (CHRA) welcomed the acquittal of several activists in the Ilocos region and the Cordillera Administrative Region in what it described as fabricated cases meant to silence those “who stand with marginalized communities.” Attorney Randy Kinaud, counsel for community doctor Ana Marie Rilloraza-Leung and an Indigenous peoples’ rights

Raffy Tulfo questions confidentiality testimony of VP witness
Nov 19, 2026
Raffy Tulfo questions confidentiality testimony of VP witness

MANILA, Philippines — Senator-Judge Raffy Tulfo challenged the need for Vice President Sara Duterte’s defense witness to continue explaining bank confidentiality on Thursday, Nov. 19, citing the Bank Secrecy Law’s exception for impeachment cases. “You’re not needed here, if you think about it,” Tulfo told lawyer and certified public accountant Rainer Dela Fuente, a former Anti-Money

Defense cites Marcos, Robredo business interests in VP Duterte trial
Nov 19, 2026
Defense cites Marcos, Robredo business interests in VP Duterte trial

MANILA, Philippines – President Ferdinand Marcos Jr. and former Vice President Leni Robredo were dragged into the impeachment trial of Vice President Sara Duterte as the defense team presented documents showing their business interests listed in their statements of assets, liabilities and net worth (SALNs). Duterte has been accused of amassing unexplained wealth, failing to

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Voice of KL

We may be unheard, but things are different now. Voice of KL represents the voice of Malaysians who want you to discover the beautiful and developed city of Malaysia.